Clinical observation of edaravone combined with argatroban in the treatment of progressive cerebral infarction
Tao Yang
Abstract
Tao Yang
Abstract
Objective To observe the clinical effects of edaravone combined with argatroban for the progressive cerebral infarction(PCI).Methods Seventy PCI patients were recruited and randomly divided into treatment group(administered with edaravone and argatroban,n=36) and control group(administered with argatroban only,n=34).Curative effect was evaluated by neurological function deficit scale and clinical manifestation.The blood and urinary routine test,liver function,renal function and electrocardiogram were also carried out before and after the treatment to detect the adverse drug reactions(ADRs).Results The grade of neurological function deficit scale in treatment group were improved significantly after treatment(P0.01).There was difference between treatment group and control group for overall response rate(P0.05) and there were no ADRs in both groups.Conclusion Edaravone combined with argatroban is an effective and safe therapeutic regimen for PCI patients.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To observe the clinical effects of edaravone combined with argatroban for the progressive cerebral infarction(PCI).Methods Seventy PCI patients were recruited and randomly divided into treatment group(administered with edaravone and argatroban,n=36) and control group(administered with argatroban only,n=34).Curative effect was evaluated by neurological function deficit scale and clinical manifestation.The blood and urinary routine test,liver function,renal function and electrocardiogram were also carried out before and after the treatment to detect the adverse drug reactions(ADRs).Results The grade of neurological function deficit scale in treatment group were improved significantly after treatment(P0.01).There was difference between treatment group and control group for overall response rate(P0.05) and there were no ADRs in both groups.Conclusion Edaravone combined with argatroban is an effective and safe therapeutic regimen for PCI patients.
Key concepts: Medicine, Argatroban, Edaravone, Conventional PCI, Cerebral infarction, Neurological deficit, Regimen, Clinical efficacy